Catalyst
Slingshot members are tracking this event:
U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
GILD |
|
|
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 01, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Emtricitabine, Rilpivirine, Tenofovir Alafena, Odefsey, Fda, Approval, Taf-based Regimen, Antiretroviral Treatment, Hiv-1